Clinical Characteristics of Young Patients With Heart Failure With Reduced Ejection Fraction in a Racially Diverse Cohort

Ignacio Zepeda, Dan L. Li, Renato Quispe, Cynthia C. Taub

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Information on the clinical and echocardiographic characteristics of young patients with heart failure with reduced ejection fraction is scant, especially among racially diverse populations. METHODS: Patients admitted to Montefiore Medical Center between 2000 and 2016 with heart failure and ejection fraction of <40% were categorized as young (18-39 years), middle-aged (40-64 years), and elderly (≥65 years). Multivariable Cox regression models were used to evaluate mortality risk. RESULTS: A total of 1032 young, 8336 middle-aged, and 13,315 elderly patients were included. Median follow-up was 36 (14-69) months. The young group had more black individuals, lower socioeconomic scores, larger left ventricular chambers, but lower N-terminal pro b-type natriuretic peptide levels (P < 0.001). Better survival outcomes were observed in the young compared to the middle-aged [hazard ratio (HR), 1.52; 95% confidence interval (CI), 1.31-1.77] and elderly (HR, 3.19; 95% CI, 2.75-3.70). After multivariable adjustments, only β-blockers were associated with a significant reduction of mortality in young patients (HR, 0.33; 95% CI, 0.22-0.51). CONCLUSION: In conclusion, young patients with heart failure with reduced ejection fraction have distinct demographic, clinical, and echocardiographic characteristics. They had lower socioeconomic status yet received more aggressive treatments and had lower mortality rates. Only β-blockers were associated with improved survival in young patients from our cohort.

Original languageEnglish (US)
Pages (from-to)80-85
Number of pages6
JournalCritical pathways in cardiology
Volume18
Issue number2
DOIs
StatePublished - Jun 1 2019

Fingerprint

Heart Failure
Confidence Intervals
Mortality
Natriuretic Peptides
Survival
Proportional Hazards Models
Social Class
Demography
Population
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical Characteristics of Young Patients With Heart Failure With Reduced Ejection Fraction in a Racially Diverse Cohort. / Zepeda, Ignacio; Li, Dan L.; Quispe, Renato; Taub, Cynthia C.

In: Critical pathways in cardiology, Vol. 18, No. 2, 01.06.2019, p. 80-85.

Research output: Contribution to journalArticle

@article{6011840229e94863845450849701ea39,
title = "Clinical Characteristics of Young Patients With Heart Failure With Reduced Ejection Fraction in a Racially Diverse Cohort",
abstract = "BACKGROUND: Information on the clinical and echocardiographic characteristics of young patients with heart failure with reduced ejection fraction is scant, especially among racially diverse populations. METHODS: Patients admitted to Montefiore Medical Center between 2000 and 2016 with heart failure and ejection fraction of <40{\%} were categorized as young (18-39 years), middle-aged (40-64 years), and elderly (≥65 years). Multivariable Cox regression models were used to evaluate mortality risk. RESULTS: A total of 1032 young, 8336 middle-aged, and 13,315 elderly patients were included. Median follow-up was 36 (14-69) months. The young group had more black individuals, lower socioeconomic scores, larger left ventricular chambers, but lower N-terminal pro b-type natriuretic peptide levels (P < 0.001). Better survival outcomes were observed in the young compared to the middle-aged [hazard ratio (HR), 1.52; 95{\%} confidence interval (CI), 1.31-1.77] and elderly (HR, 3.19; 95{\%} CI, 2.75-3.70). After multivariable adjustments, only β-blockers were associated with a significant reduction of mortality in young patients (HR, 0.33; 95{\%} CI, 0.22-0.51). CONCLUSION: In conclusion, young patients with heart failure with reduced ejection fraction have distinct demographic, clinical, and echocardiographic characteristics. They had lower socioeconomic status yet received more aggressive treatments and had lower mortality rates. Only β-blockers were associated with improved survival in young patients from our cohort.",
author = "Ignacio Zepeda and Li, {Dan L.} and Renato Quispe and Taub, {Cynthia C.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1097/HPC.0000000000000172",
language = "English (US)",
volume = "18",
pages = "80--85",
journal = "Critical Pathways in Cardiology",
issn = "1535-282X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Clinical Characteristics of Young Patients With Heart Failure With Reduced Ejection Fraction in a Racially Diverse Cohort

AU - Zepeda, Ignacio

AU - Li, Dan L.

AU - Quispe, Renato

AU - Taub, Cynthia C.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - BACKGROUND: Information on the clinical and echocardiographic characteristics of young patients with heart failure with reduced ejection fraction is scant, especially among racially diverse populations. METHODS: Patients admitted to Montefiore Medical Center between 2000 and 2016 with heart failure and ejection fraction of <40% were categorized as young (18-39 years), middle-aged (40-64 years), and elderly (≥65 years). Multivariable Cox regression models were used to evaluate mortality risk. RESULTS: A total of 1032 young, 8336 middle-aged, and 13,315 elderly patients were included. Median follow-up was 36 (14-69) months. The young group had more black individuals, lower socioeconomic scores, larger left ventricular chambers, but lower N-terminal pro b-type natriuretic peptide levels (P < 0.001). Better survival outcomes were observed in the young compared to the middle-aged [hazard ratio (HR), 1.52; 95% confidence interval (CI), 1.31-1.77] and elderly (HR, 3.19; 95% CI, 2.75-3.70). After multivariable adjustments, only β-blockers were associated with a significant reduction of mortality in young patients (HR, 0.33; 95% CI, 0.22-0.51). CONCLUSION: In conclusion, young patients with heart failure with reduced ejection fraction have distinct demographic, clinical, and echocardiographic characteristics. They had lower socioeconomic status yet received more aggressive treatments and had lower mortality rates. Only β-blockers were associated with improved survival in young patients from our cohort.

AB - BACKGROUND: Information on the clinical and echocardiographic characteristics of young patients with heart failure with reduced ejection fraction is scant, especially among racially diverse populations. METHODS: Patients admitted to Montefiore Medical Center between 2000 and 2016 with heart failure and ejection fraction of <40% were categorized as young (18-39 years), middle-aged (40-64 years), and elderly (≥65 years). Multivariable Cox regression models were used to evaluate mortality risk. RESULTS: A total of 1032 young, 8336 middle-aged, and 13,315 elderly patients were included. Median follow-up was 36 (14-69) months. The young group had more black individuals, lower socioeconomic scores, larger left ventricular chambers, but lower N-terminal pro b-type natriuretic peptide levels (P < 0.001). Better survival outcomes were observed in the young compared to the middle-aged [hazard ratio (HR), 1.52; 95% confidence interval (CI), 1.31-1.77] and elderly (HR, 3.19; 95% CI, 2.75-3.70). After multivariable adjustments, only β-blockers were associated with a significant reduction of mortality in young patients (HR, 0.33; 95% CI, 0.22-0.51). CONCLUSION: In conclusion, young patients with heart failure with reduced ejection fraction have distinct demographic, clinical, and echocardiographic characteristics. They had lower socioeconomic status yet received more aggressive treatments and had lower mortality rates. Only β-blockers were associated with improved survival in young patients from our cohort.

UR - http://www.scopus.com/inward/record.url?scp=85066831531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066831531&partnerID=8YFLogxK

U2 - 10.1097/HPC.0000000000000172

DO - 10.1097/HPC.0000000000000172

M3 - Article

C2 - 31094734

AN - SCOPUS:85066831531

VL - 18

SP - 80

EP - 85

JO - Critical Pathways in Cardiology

JF - Critical Pathways in Cardiology

SN - 1535-282X

IS - 2

ER -